TROP2 promotes proliferation, migration and metastasis of gallbladder cancer cells by regulating PI3K/AKT pathway and inducing EMT
Metrics: PDF 1025 views | HTML 1079 views | ?
Xinxing Li1,*, Shifeng Teng1,*, Yanyan Zhang1,*, Weigang Zhang1, Xianwen Zhang1, Kai Xu1, Houshan Yao1, Jun Yao1, Haolu Wang2, Xiaowen Liang2 and Zhiqian Hu1
1Department of General Surgery, Changzheng Hospital, The Second Military Medical University, Shanghai 200003, China
2Therapeutics Research Centre, School of Medicine, The University of Queensland, Princess Alexandra Hospital, Woolloongabba QLD 4102, Australia
*These authors have contributed equally to this work
Xinxing Li, email: email@example.com
Xiaowen Liang, email: firstname.lastname@example.org
Zhiqian Hu, email: email@example.com
Keywords: gallbladder cancer, TROP2, AKT, EMT
Received: September 30, 2016 Accepted: March 21, 2017 Published: April 03, 2017
The human trophoblast cell surface antigen 2 (TROP2) is overexpressed in many cancers. However, its effect on proliferation, migration and metastasis of gallbladder cancer remains unclear. In this study, we found that TROP2 was highly expressed in gallbladder cancer. Overexpression of TROP2 was associated with poor prognosis. Knockdown of TROP2 in gallbladder cancer cell lines strongly inhibited the cell proliferation, clone formation, invasion and migration in vitro, while TROP2 overexpression had opposite effects. In addition, knockdown of TROP2 increased the expression of total PTEN, p-PTEN and PDK-1 but reduced p-AKT via PI3K/AKT pathway. TROP2 downregulation also inhibited vimentin and increased E-cadherin expression during epithelial-mesenchymal transition (EMT). Moreover, gallbladder cancer cells with TROP2 knockdown formed smaller xenografted tumors in vivo. In consistent with in vitro results, TROP2 inhibition decreased Akt phosphorylation, increased PTEN expression and postponed EMT of gallbladder cancer cells in vivo. In conclusion, we revealed that TROP2 promoted the proliferation, migration and metastasis of gallbladder cancer cells by regulating PI3K/AKT pathway and inducing EMT. TROP2 could serve as a potential prognostic biomarker and therapeutic target for the clinical management of gallbladder cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.